Abstract: The present invention discloses a compound of formula I, a composition including the same and use thereof, wherein A, X, Y, L, M and W are as defined herein. The compound disclosed in the present invention can be used for treating diseases related to over-activation or over-expression of JAK3 kinase, such as autoimmune diseases, lung injury, and organ transplant rejection. In vitro experiments show that this series of compounds have a good inhibitory activity on the JAK3 kinase and have good application prospects in the field of medicine.

Abstract: A molecular marker for diagnosing, prognosis, evaluating, and treating cardiac fibrosis and belongs to the technical field of biomedicine. The present disclosure provides a molecular marker capable of diagnosing cardiac fibrosis, assessing the severity of cardiac fibrosis, evaluating the prognosis of cardiovascular disease with cardiac fibrosis, or evaluating the prognosis of acute myocardial infarction. The molecular marker comprises hepatocyte growth factor. It has been found that HGF is significantly elevated in the plasma of patients with cardiac fibrosis and also considerably elevated in patients with aortic stenosis before surgery. Therefore, HGF can be used to diagnose cardiac fibrosis and evaluate its severity.

Abstract: This disclosure pertains to codon-optimized GBA1 polynucleotides that encode a GCase protein, with a portion of the coding sequence deviating from the wild-type. Additionally, the disclosure encompasses expression constructs, vectors, viral particles, or compositions containing the disclosed polynucleotide. Furthermore, it encompasses methods and applications of these polynucleotides, expression constructs, vectors, viral particles, or compositions, including treatment of the disease or condition is associated with GCase deficiency.

Abstract: Compounds, proteins, crosslinked proteins, compositions thereof, and methods of making and uses thereof. A compound, which may be an alpha-amino acid, comprises one or more beta-lactam group(s), one or more triazole groups, substituted analogs thereof, or any combination thereof. A protein comprises one or more amino acid residue(s), each residue comprising a beta-lactam group, a triazole group, or a substituted analog thereof. A protein can be made by a recombinant method using one or more compound(s). A cross-linked protein comprises one or more intramolecular crosslink(s) and/or one or more intermolecular crosslink(s). In various examples, a crosslink is formed, e.g., in solution or in vivo, by a proximity enabled beta-lactam ring opening reaction or an acyl transfer reaction between a beta-lactam group or a triazole group and a nucleophilic side-chain group, where both groups are on a single polypeptide or on different polypeptide chains. Crosslinked protein(s) can be used in methods of treatment.

Abstract: A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.

Abstract: A communication method and an apparatus are provided. The method includes: a first node receives a resource scheduling message transmitted by an upper-level node. The resource scheduling message carries template identification information indicating a target time slot allocation template to be used. The first node determines a transmission time slot of the first node based on indication information that is included in the target time slot allocation template and that is used for allocating time slots to a plurality of nodes. Because a byte length occupied by the template identification information is far less than a byte length occupied by time slot allocation information corresponding to each node, a length of the resource scheduling message can be greatly shortened, and even if a quantity of nodes in the communication system increases, the length of the resource scheduling message does not increase.

Abstract: A titanium alloy product includes a titanium alloy substrate and a plurality of first holes defined in a surface of the titanium alloy substrate. The first holes have an opening on the surface of the titanium alloy substrate and an inner wall connecting with the opening, a diameter of the inner space is greater than a diameter of the opening. The product tensile strength of bonding between the titanium alloy product and a material part filled in the first holes is very high. A housing with the titanium alloy product and a method for manufacturing the titanium alloy product are also disclosed.

Abstract: The present invention relates to the field of wound healing. More specifically, the present invention provides methods and compositions useful for improved wound healing via autologous stem cell mobilization. In one embodiment, a method for improving wound healing in a patient comprises administering to the patient a therapeutically effective amount of a stem cell mobilizer and a low dose of an immunosuppressive agent.

Abstract: A system and method includes soft-segment based rules optimization that can mitigate the overall false positives while maintaining 100% true positive detection. The soft clustering allows real-time re-assignment of an account to a dominate archetype behavior, as well as rule optimization based on a logical order with more relaxation on thresholds for the most inefficient rules is performed within each archetype. The rule optimization provides false positive reduction compared to a baseline rule system. The method can be used to reduce false positives for any rule-based detection system in which the same true positive detection is required.

Abstract: A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.

Abstract: A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.

Abstract: A variant AAV capsid protein, comprising an amino acid sequence corresponding to the position amino acids 585 to 597 or 598 of AAV8 or the position amino acids 583 to 595 or 596 of AAV9, and the polynucleotide, host cells, vectors, AAV virion or the pharmaceutical composition thereof. A method of treating disease, the method comprising administering to a subject in need thereof an effective amount of the recombinant AAV virion.

Abstract: A titanium alloy product includes a titanium alloy substrate and a plurality of first holes defined in a surface of the titanium alloy substrate. The first holes have an opening on the surface of the titanium alloy substrate and an inner wall connecting with the opening, a diameter of the inner space is greater than a diameter of the opening. The product tensile strength of bonding between the titanium alloy product and a material part filled in the first holes is very high. A housing with the titanium alloy product and a method for manufacturing the titanium alloy product are also disclosed.

Abstract: An AAV library, comprising AAV variants having an amino acid sequence corresponding to the position amino acids 585 to 597 or 598 of AAV8 or the position amino acids 583 to 595 or 596 of AAV9, and the polynucleotide, host cells, thereof. A method of generating and screening an AAV library and its use.

Abstract: The present invention relates to the field of wound healing. More specifically, the present invention provides methods and compositions useful for improved wound healing via autologous stem cell mobilization. In one embodiment, a method for improving wound healing in a patient comprises administering to the patient a therapeutically effective amount of a stem cell mobilizer and a low dose of an immunosuppressive agent.

Abstract: The present invention relates to the field of wound healing. More specifically, the present invention provides methods and compositions useful for improved wound healing via autologous stem cell mobilization. In one embodiment, a method for improving wound healing in a patient comprises administering to the patient a therapeutically effective amount of a stem cell mobilizer and a low dose of an immunosuppressive agent.

Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.